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Conclusion: Distant metastasis remains the major issue in the 
management of LARC. This study demonstrated improvement 
in pCR, as well as the potential to achieve higher survival 
rates, including DFS. Waiting for randomized phase III trials 
long-term follow-up data, OXP should be considered as 
feasible and valid neo-adjuvant treatment option. The low 
rate of severe toxicity and the effective benefit on pCR and 
peri-operative metastasis support this concomitant CHT 
schedule for LARC. 
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Purpose or Objective: To compare the oncologic outcome of 
total mesorectal excision (TME) to local excision (LE) in 
"early" clinical T3 rectal cancer patients who received 
preoperative radiation therapy.  
 
Material and Methods: "Early" clinical T3 patients, who 
underwent preoperative radiation therapy followed by TME or 
LE at Asan Medical Center between January 2007 and 
December 2013 were retrospectively analyzed. "Early" clinical 
T3 was defined as extramural extension ≤ 5mm, 
circumferential resection margin negative and lateral lymph 
node negative in pretreatment magnetic resonance imaging. 
A one-to-one propensity case-matched analysis was used with 
covariates of baseline characteristics. Local recurrence free 
survival (LRFS), disease free survival (DFS), overall survival 
(OS) were compared between the matched two groups. 
 
Results: A total of 425 patients were identified; 366 
underwent TME and 59 underwent LE. The median follow-up 
period was 47 months. After propensity score-matching, we 
obtained 55 matched pairs. There were no significant 
differences in 3-year LRFS (95.8% vs 94.2%, p=0.927), DFS 
(85.7% vs 90.8%, p=0.473), OS (96.2% vs 100%, p=0.987) 
between TME and LE groups.  
 
Conclusion: In "early" clinical T3 rectal cancer, local excision 
could be a feasible alternative to mesorectal excision after 
preoperative chemoradiation.  
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Purpose or Objective: Cervical intraepithelial neoplasia 
(CIN) and anal squamous cell carcinoma (SCC) are both 
causally associated with human papilloma virus infection 
(HPV). Women who have an HPV infection of the cervix are at 
a higher risk of HPV infection of the anal canal with the same 
HPV subtype(1). The incidence of HPV infection and related 
cancers is increasing in developed nations(2). Until the 
impact of widespread HPV vaccination is manifest, 
presentation with multiple HPV related malignancies will 
become a more common clinical scenario. Our objective was 
to identify the proportion of women with anal cancer who 
had a history of CIN or invasive cervical cancer (ICC) and 
discuss the implications for future practice.  
 
Material and Methods: The medical records and 
histopathology of all consecutive women treated definitively 
for anal cancer at our centre between January 2004 and July 
2015 were reviewed. A case was defined as a woman 
reporting a history of CIN or ICC treated with either a cone 
biopsy or hysterectomy. We extracted treatment details of 
both the anal cancer and CIN or ICC, demographic and 
outcome data. Women with a previous abnormal pap smear 
or low grade cervical dysplasia were not included as a case.  
 
Results: Eight cases (25%) were identified; Stage III (63%), I, 
II, IV (each 12.5%). The women were HIV negative, aged 36-
62 years and diagnosed with HPV positive anal SCC 10-40 
years after their initial diagnosis. Of the remaining 24 
women, Nine had no prior history, Four had a previous 
abnormal pap smear, one a partial hysterectomy for unknown 
reason, two a hysterectomy for benign uterine disease and 
eight no recorded gynaecological history. Seven women had 
definitive chemoradiotherapy and one had sequential 
chemotherapy and radiotherapy (Stage IV). All were alive and 
disease free at follow up. 
 
Conclusion: One quarter of women with anal SCC had a 
previous history of CIN or ICC. This may be an underestimate 
as a gynaecological history was missing in 25% of patients. 
There are several implications for practice: the importance 
of specifically elucidating a history of HPV-related disease 
such as warts, CIN or ICC on history; secondly, to have a high 
index of suspicion when these women present with bowel 
symptoms; third, that this represents a high risk group of 
women who may benefit from participation in anal pap 
screening programs similar to that being investigated in high 
risk men. 
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Purpose or Objective: To test the relationship between 
dosimetric data and pathological response in a series of 52 
patients treated with combined pre-operative 
chemoradiation (CRT) for local advanced rectal cancer.. 
 
Material and Methods: We studied 52 consecutive patients 
treated with pre-operative CRT for locally advanced rectal 
cancer (T3-4N0M0 or any TN+M0, G1-3). Total dose 
prescribed was 44 Gy (2 Gy/fx) (Group 1, n = 10) or 45 Gy 
(1.8 Gy/fx) (Group 2, n = 42), delivered using helical 
Tomotherapy (HT). A concomitant Capecitabine-based 
chemotherapy was also delivered. All patients underwent 
surgery 6 to 8 weeks after the end of CRT. Surgery consisted 
of low anterior resection (LAR) or abdominoperineal excision 
(APR), depending on the tumor distance from anal margin. 
For all patients, we calculated pathological response through 
difference between TNM clinical staging and TNM 
pathological staging such as by pathological Dworak tumor 
regression score (TRG). We tested the relationship between 
pathological response and planning target volume (PTV) 
dosimetric criteria in agreement with ICRU 83 and internal 
guidelines. Selected parameters were: Dmax, Dmin, 
Dmean,D98,D95, D2, V95,V100 ,V107, V110 and target 
volume (cc). Non-parametric statistical analysis (Wilcoxon, U-
Mann-Whitney, Kruskal-Wallis tests) was performed using 
SPSS.21 software (significant level p < 0.05). Planning 
dosimetric data were extracted from patient archives using 
VODCA 5.4.0. 
 
Results: Results: A significant reduction in TNM staging was 
observed post-treatment (p < 0.001 and p < 0.010 for T & N, 
respectively). Furthermore, 3 patients presented a total 
remission (5.8%) and 30 remained stable (57.7%). For Group 
1, average values and standard deviation of Dmean, Dmin and 
Dmax (Gy) were 44.5 ± 0.4, 30.4 ± 3.6, and 47.2 ± 0.3, while 
for Group 2 were 45.1 ± 0.3, 33.1 ± 3.5, and 48.1 ± 0.6. Dose 
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fractionation was not significant for both TNM and TRG (p > 
0.100). Among dosimetric parameters, Dmin resulted 
statistically different depending on the patient T staging 
variation (p < 0.005). Specifically, focusing on the 21 patients 
with favourable pathological response, significant correlation 
was found with the T index variation (ρSpearman = -0.667, p 
= 0.001), with higher Dmin related to patients undergoing 
total remission. No other dosimetric parameters resulted 
associated with clinical tumor regression outcomes.  
 
Conclusion: In this series we found a statistically significant 
correlation between T staging regression and the Dmin to the 
PTV. Patients with partial or complete pathological response 
showed a higher Dmin when compared to patients with no 
change in TNM staging. Further studies are needed to 
understand if there is any relation between the site of 
underdosages and the tumor site.  
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Purpose or Objective: The standard treatment for locally 
advanced rectal cancer (LARC) is neoadjuvant chemo-
radiation (CRT) followed by mesorectal excision. However, 
surgical specimen histopathology demonstrates a complete 
pathological response (pCR) in almost 30% of cases. In 
consequence, these patients (pts) may benefit from 
conservative management.  
The aim of this study is to evaluate the role of 18F-FDG-
PET/CT in pts with LARC in the prediction of pCR after 
treatment with CRT. 
 
Material and Methods: From September 2009 to May 2014, 39 
pts (mean age: 62 years, range 40-83) with LARC underwent 
18F-FDG-PET/CT for staging and radiotherapy (RT) treatment 
planning. Tumour location within rectum: superior: 17 
(43.85%); middle: 14 (35.89%); inferior: 8 (20.51%). Histology: 
adenocarcinoma: 37 (94.87%); mucinous adenocarcinoma: 2 
(5.13%). Tumour staging: II: 7 (17.95%); III: 31 (79.48%); IV 
(resected liver metastases disease): 1 (2.56%).  
All pts received conformal RT (Nodal PTV: 4500 cGy, Tumor 
PTV: 5040 cGy) with concurrent Capecitabine, before 
undergoing either low anterior resection (32pts-82.05%) or 
abdomino-perineal resection (7pts-17.95%).  
The tumour regression grade (TRG) according to Mandard´s 
criteria was assessed by the pathologist. Pts were classified 
into two groups: responders (TRG 1 and 2) and non-
responders (TRG 3 to 5). The TRG was correlated with 18F-
FDG-PET/CT parameters (tumour volume, tumour SUVmax 
and nodal SUVmax). 
 
Results: Following CRT, 7/39 pts (17.94%) showed no 
evidence of residual tumour in the surgical specimen (pCR). 
By TRG status, 14 pts (35.9%) were classified as responders 
and 25 (64.10%) as non-responders. When analyzing 18F-FDG-
PET/CT parameters, no significant difference was found 
between responders and non-responders for: tumour volume 
(mean: 5.84cm3 vs 6.24 cm3, p=0.35); tumour SUVmax (21.95 
vs 20.73, p=0.61); nodal SUVmax (4.73 vs 7.56, p=0.12) or 
staging (6.71 vs 7.56, p=0.23). Histopathological responders 
had better overall survival compared to non-responders, 
however this was not statistically significant (617 vs 269 days, 
p=0.37).  
 
Conclusion: In our cohort, 18F-FDG-PET/CT parameters 
cannot predict the tumour response to CRT. Nevertheless, 
higher levels of SUVmax and bigger tumour volumes are found 
in the non-responders group and also worst overall survival. 
Stronger conclusions should be established in this matter in 
order to select patients for an organ-preservation safely.  
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Purpose or Objective: The approach to patients with lung 
metastasis from primary colon-rectal cancer is based on 
systemic therapy and the role of stereotactic body 
radiotherapy (SBRT) is still to be investigated. The present 
work aims to study the impact of SBRT in oligometastatic 
patients with lung metastasis from colon-rectal cancer. 
 
Material and Methods: From May 2010 to March 2015, 33 
consecutive patients (median age 66 years, range 31-88) with 
lung metastasis from colon-rectal cancer were treated with 
SBRT. All patients were treated using Image Guided 
Radiotherapy (IGRT) and stratified according to K-RAS and B-
RAF genotype. The systemic progression free survival and 
local control were the primary and secondary endpoint 
evaluated respectively. 
 
Results: A total of 56 active lesions were treated. After a 
median follow-up of 12.6 months, median OS was 10.5 
months. The radiotherapy dose delivered and the schedule 
adopted were 24-27 Gy as a single fraction and 27-42 Gy/3 
fractions. Nineteen out of 33 patients were affected by rectal 
cancer while 14 patients by colon cancer. Median Planning 
Target Volume value was 21.45 cc (range 6-156). Mean local 
relapse was recorded in 23 lesions (41.1%) at a median 
interval of 19.3 months (range 5-37). By the way, 23 out 33 
patients (69.7%) experienced systemic progression after a 
mean time of 12.6 months (1-24) from SBRT. No differences 
of local or systemic control were observed considering K-RAS 
and B-RAS genotype. Severe toxicity were not recorded.  
 
Conclusion: The results of this study suggest that SBRT could 
represent a safe and valid approach to oligometastatic 
patients with lung metastasis from colon-rectal cancer. 
However, further studies are needed in order to better 
characterize patients potentially suitable for SBRT. 
 
EP-1299  
Tomotherapy for anal cancer: analysis of toxicity and 
response in a dual institution experience 
P. Bonomo
1University of Florence, Radiation Oncology, Firenze, Italy 
1, B. Meduri2, E. D'Angelo2, A. Galardi1, C. Delli 
Paoli1, C. Tata2, G. De Marco2, I. Desideri1, F. Bertoni2, L. 
Livi1 
2University Hospital of Modena, Radiation Oncology, Modena, 
Italy 
 
Purpose or Objective: The purpose of our study is to report 
on the acute toxicity and response to treatment in patients 
affected by squamous cell anal carcinoma (SCAC) that 
underwent tomotherapy (TO) at 2 institutions.  
 
Material and Methods: A cohort of 39 patients affected by 
SCAC and treated with TO between December 2009 and July 
2015 was retrospectively analyzed. Concurrent chemotherapy 
(CT) was always administered except in patients unfit for 
intensive therapy due to comorbidity and/or with early stage 
disease (T1-T2N0). The choice of CT regimen was left to the 
discretion of the treating institution, as well as the IMRT 
schedule adopted. The dose/fractionation prescribed to PTV1 
(high-risk volume), PTV2 (intermediate-risk volume) and PTV3 
(low-risk volume) ranged between 66– 50 Gy, 50.4 – 45 Gy 
and 46.2 – 36 Gy, respectively, at a corresponding dose per 
fraction range of 2.2 – 1.8 Gy for PTV1, 2 – 1.67 Gy for PTV2, 
and 1.65 – 1.5 Gy for PTV3, delivered in a range of 25-33 
daily fractions. Acute toxicity was scored according to NCI – 
CTCAE v.4. Response was assessed at 12 weeks after the end 
of treatment via digital rectal exam and anoscope. 
